Literature DB >> 15539797

Impact of growth hormone status on body composition and the skeleton.

Annice Mukherjee1, Robert D Murray, Stephen M Shalet.   

Abstract

Severe growth hormone (GH) deficiency (GHD) induces a well-defined clinical entity encompassing, amongst the most reported features, abnormalities of body composition, in particular increased fat mass, especially truncal, and reduced lean body mass. The results from virtually all treatment studies are in agreement that GH replacement improves the body composition profile of GHD patients by increasing lean body mass and reducing fat mass. More recently, the observations have been extended to adults with partial GHD, defined by a peak GH response to insulin-induced hypoglycaemia of 3-7 microg/l. These patients exhibit abnormalities of body composition similar in nature to those described in adults with severe GHD; these include an increase in total fat mass of around 3.5 kg and a reduction of lean body mass of around 5.5 kg. The increase in fat mass is predominantly distributed within the trunk. The degree of abnormality of body composition is intermediate between that of healthy subjects and that of adults with GHD. The impact of GH replacement on body composition in adults with GH insufficiency, although predictable, has not been formally documented. The skeleton is another biological endpoint affected by GH status: in adults with severe GHD, low bone mass has been reported using dual energy x-ray absorptiometry (DEXA) and other quantitative methodologies. The importance of low bone mass, in any clinical setting, is as a surrogate marker for the future risk of fracture. Several retrospective studies have documented an increased prevalence of fractures in untreated GHD adults. Hypopituitary adults with severe GHD have reduced markers of bone turnover which normalize with GH replacement, indicating that GH, directly or via induction of insulin-like growth factor-I, is intimately involved in skeletal modelling. Whilst the evidence that GH plays an important role in the acquisition of bone mass during adolescence and early adult life is impressive, the impact of GHD acquired later in adulthood is less clear. Recently we examined the relationship between bone mineral density (BMD) and age in 125 untreated adults with severe GHD using DEXA. A significant positive correlation was observed between BMD (z-scores) and age at all skeletal sites studied. Overall, few patients, except those aged less than 30 years, had significantly reduced bone mass (i.e. a BMD z-score of less than -2); correction of BMD to provide a pseudo-volumetric measure of BMD suggested that reduced stature of the younger patients may explain, at least in part, this higher frequency of subnormal BMD z-scores. Despite normal BMD, however, an increase in fracture prevalence may still be observed in elderly GHD adults as a consequence of increased falls related to muscle weakness and visual field defects. 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539797     DOI: 10.1159/000080497

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  9 in total

1.  Absence of ghrelin protects against early-onset obesity.

Authors:  Katherine E Wortley; Juan-Pablo del Rincon; Jane D Murray; Karen Garcia; Keiji Iida; Michael O Thorner; Mark W Sleeman
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  What are critical outcome measures for patients receiving pituitary replacement following brain injury?

Authors:  Sorin G Beca; Walter M High; Brent E Masel; Kurt A Mossberg; Randall J Urban
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

3.  Body composition predictors of skeletal integrity in obesity.

Authors:  Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Martin Torriani; Karen K Miller; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2016-03-16       Impact factor: 2.199

4.  Determinants of bone mineral density in obese premenopausal women.

Authors:  Miriam A Bredella; Martin Torriani; Reza Hosseini Ghomi; Bijoy J Thomas; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Anne Breggia; Clifford J Rosen; Karen K Miller
Journal:  Bone       Date:  2010-12-30       Impact factor: 4.398

5.  Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women.

Authors:  Miriam A Bredella; Martin Torriani; Reza Hosseini Ghomi; Bijoy J Thomas; Danielle J Brick; Anu V Gerweck; Clifford J Rosen; Anne Klibanski; Karen K Miller
Journal:  Obesity (Silver Spring)       Date:  2010-05-13       Impact factor: 5.002

6.  A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis.

Authors:  Victoria E DeMambro; Masanobu Kawai; Thomas L Clemens; Keertik Fulzele; Jane A Maynard; Caralina Marín de Evsikova; Kenneth R Johnson; Ernesto Canalis; Wesley G Beamer; Clifford J Rosen; Leah Rae Donahue
Journal:  J Endocrinol       Date:  2009-12-23       Impact factor: 4.286

7.  Changes in skeletal muscle gene expression following clenbuterol administration.

Authors:  Diane M Spurlock; Tara G McDaneld; Lauren M McIntyre
Journal:  BMC Genomics       Date:  2006-12-20       Impact factor: 3.969

Review 8.  Bone regeneration and stem cells.

Authors:  K Arvidson; B M Abdallah; L A Applegate; N Baldini; E Cenni; E Gomez-Barrena; D Granchi; M Kassem; Y T Konttinen; K Mustafa; D P Pioletti; T Sillat; A Finne-Wistrand
Journal:  J Cell Mol Med       Date:  2011-04       Impact factor: 5.310

9.  Baseline Body Composition in Prepubertal Short Stature Children with Severe and Moderate Growth Hormone Deficiency.

Authors:  Pawel Matusik; Marta Klesiewicz; Karolina Klos; Martyna Stasiulewicz; Aleksandra Barylak; Patrycja Nazarkiewicz; Ewa Malecka-Tendera
Journal:  Int J Endocrinol       Date:  2016-08-30       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.